HAE

In the past six months, Haemonetics Corp. (HAE) stock price experienced significant positive movement, surging to a new 52-week high of $119.00 in October 2026. This increase was largely driven by the announcement of a non-exclusive plasma supply agreement with CSL Plasma Inc., which plans to deploy Haemonetics' NexSys PCS devices with Persona PLUS technology across its U.S. plasma collection centers by the end of 2027, expected to expand demand for Haemonetics' plasma collection technology and recurring disposable products. Earlier, in August 2026, Haemonetics reported better-than-expected first-quarter fiscal year 2027 (Q2 CY2026) financial results, with revenue of $339.4 million and adjusted EPS of $1.14 surpassing analyst estimates. Following these strong results, management raised its full-year reported revenue growth guidance to 5% to 8%. Analyst sentiment has been favorable, with several research firms increasing their price targets and maintaining 'Buy' or 'Outperform' ratings on the stock. Over the past six months, the stock has seen an increase of 103.48%.